~0 spots leftby Jun 2025

Triapine for Uterine Cancer

Recruiting in Palo Alto (17 mi)
+6 other locations
RL
Overseen byRebecca L Stone
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Waitlist Available
Sponsor: National Cancer Institute (NCI)
No Placebo Group

Trial Summary

What is the purpose of this trial?

This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot take medications that are inhibitors or inducers of triapine, or those associated with methemoglobinemia. You will be counseled on potential drug interactions during the enrollment process.

What data supports the idea that Triapine for Uterine Cancer is an effective treatment?

The available research shows that Triapine has been studied for its effectiveness in treating cervical cancer, which is similar to uterine cancer. In clinical trials, Triapine was combined with another drug, cisplatin, and radiation therapy, and it helped control the disease over a long period. However, some studies suggest that Triapine alone may not be very effective against solid tumors due to its short time in the body and quick breakdown. Researchers are exploring ways to improve its effectiveness, such as using special carriers to deliver the drug more efficiently. While there is promising data for cervical cancer, specific data for uterine cancer is not provided in the available research.12345

What safety data is available for Triapine in treating cancer?

Triapine, also known as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, has been evaluated in several clinical trials for its safety and efficacy. A Phase I trial identified dose-limiting toxicities and the maximum-tolerated dose for a 96-hour intravenous infusion in patients with advanced cancer. Additionally, Triapine has been studied in combination with cisplatin radiochemotherapy for cervical cancer, showing long-term disease control. However, challenges such as short plasma half-life and fast metabolism have been noted, leading to research into liposomal formulations to improve its pharmacokinetic properties. Overall, Triapine has been shown to enhance radiochemosensitivity and induce apoptosis in cancer cells, but further studies are needed to optimize its delivery and efficacy.12346

Is the drug Triapine a promising treatment for uterine cancer?

Triapine is a promising drug because it helps make cancer treatments more effective by slowing down the repair of cancer cells' DNA. This can lead to better control of the disease and improve survival rates in patients with certain types of cancer.12345

Research Team

RL

Rebecca L Stone

Principal Investigator

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Eligibility Criteria

This trial is for adults with specific types of uterine cancer who are planning to have a hysterectomy and haven't had previous cancer treatment. They must be in good health overall, with proper kidney, liver, and blood cell function. People with certain heart conditions or infections like hepatitis B or C need to have them under control. Pregnant women can't join, and participants should understand the study well enough to consent.

Inclusion Criteria

I have not had any previous cancer treatment for endometrial cancer.
Platelets >= 100,000/mcL
My cancer is a specific type of uterine cancer called serous adenocarcinoma.
See 19 more

Exclusion Criteria

I do not have any unmanaged ongoing illnesses.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine
Patients with psychiatric illness/social situations that would limit compliance with study requirements
See 6 more

Treatment Details

Interventions

  • Triapine (Ribonucleotide Reductase Inhibitor)
Trial OverviewThe trial is testing Triapine's effectiveness when added to standard surgery followed by chemotherapy or radiation therapy for uterine cancers. Researchers will look at tissue markers from samples collected during surgery to see how the tumor cells respond.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (triapine, surgical resection)Experimental Treatment4 Interventions
Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+
Dr. Douglas R. Lowy profile image

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli profile image

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School

Findings from Research

In a phase I trial involving 21 patients with advanced cancer, the recommended phase II dose of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) was determined to be 120 mg/m²/day administered via a 96-hour intravenous infusion every 2 weeks, with manageable dose-limiting toxicities such as neutropenia and hyperbilirubinemia.
While there were no objective responses to treatment, some patients experienced prolonged disease stabilization and decreases in serum tumor markers, indicating potential efficacy in managing advanced cancer.
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.Wadler, S., Makower, D., Clairmont, C., et al.[2007]
Triapine, a ribonucleotide reductase inhibitor, is being evaluated for treating cervical and vulvar cancer in combination with cisplatin chemoradiation, and researchers are exploring its oral administration to simplify treatment logistics.
A validated LC-MS/MS assay was developed to accurately quantify triapine in human plasma, which will help assess its pharmacokinetics and oral bioavailability, ensuring the method meets FDA standards for bioanalytical validation.
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.Matsumoto, J., Kiesel, BF., Parise, RA., et al.[2018]
In a study of 24 patients with advanced-stage cervical cancer, triapine combined with cisplatin and radiation therapy demonstrated a low 3-year pelvic locoregional relapse rate of 4%, indicating its potential effectiveness in treatment.
The treatment resulted in high disease-free survival (80%) and overall survival (82%) rates over a median follow-up of 3.4 years, suggesting that triapine is a safe and promising option for patients with untreated cervical cancer.
Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.Kunos, CA., Sherertz, TM.[2021]

References

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. [2007]
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. [2018]
Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer. [2021]
Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes. [2022]
Triapine Analogues and Their Copper(II) Complexes: Synthesis, Characterization, Solution Speciation, Redox Activity, Cytotoxicity, and mR2 RNR Inhibition. [2021]
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. [2015]